Want to see HK:0897 full AI Analyst Report?
0897 Stock Chart & Stats
HK$0.36
>-HK$0.01(-1.67%)
At close: 4:00 PM EST
HK$0.36
>-HK$0.01(-1.67%)
Day’s Range― - ―
52-Week RangeHK$0.27 - HK$0.50
Previous CloseN/A
Volume490.00K
Average Volume (3M)483.69K
Market Cap
HK$384.46M
Enterprise ValueHK$560.58
Total Cash (Recent Filing)HK$147.44M
Total Debt (Recent Filing)HK$279.29M
Price to Earnings (P/E)95.8
Beta0.40
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield84.69%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,114,382,900
10 Day Avg. Volume1,146,819
30 Day Avg. Volume483,689
Financial Highlights & Ratios
PEG Ratio-2.14
Price to Book (P/B)0.31
Price to Sales (P/S)0.54
P/FCF Ratio6.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
DeleveragingSharp debt reduction materially lowers financial risk and interest-related pressure while improving flexibility. A debt-to-equity ratio of about 0.24 gives the company more capacity to manage volatility, support operations, and allocate capital without relying as heavily on external financing.
Positive Cash GenerationPositive operating and free cash flow provides internal funding despite thin reported earnings. This supports ongoing operations and reduces dependence on borrowing, while giving management resources to maintain the retail and distribution platform over the next several quarters.
Improved Gross MarginThe stronger gross margin indicates improved economics at the product level, potentially reflecting a better mix or more effective gross-profit management. If sustained, this improvement can help offset revenue pressure and provide a stronger foundation for restoring positive operating profitability.
Bears Say
Sustained Revenue ContractionPersistent revenue contraction signals weakening scale across the company’s retail and distribution activities. Continued top-line pressure can reduce operating leverage, limit reinvestment capacity, and make it harder for the improved gross margin to translate into durable earnings growth.
Thin Profitability And Operating LossVery thin net profitability leaves little buffer against cost pressure or further revenue weakness. The continued operating loss shows that gross profit is not yet covering the full cost base, limiting earnings quality and making the recent positive net income less durable.
Weaker And Volatile Free Cash FlowAlthough free cash flow remains positive, its sharp year-over-year decline and historical volatility reduce confidence in consistent cash conversion. Less dependable cash generation could constrain internally funded growth and weaken the company’s ability to absorb operational setbacks.
Wai Yuen Tong Medicine Holdings Limited News
0897 FAQ
What was Wai Yuen Tong Medicine Holdings Limited’s price range in the past 12 months?
Wai Yuen Tong Medicine Holdings Limited lowest stock price was HK$0.27 and its highest was HK$0.49 in the past 12 months.
What is Wai Yuen Tong Medicine Holdings Limited’s market cap?
Wai Yuen Tong Medicine Holdings Limited’s market cap is HK$384.46M.
When is Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date?
Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date is Dec 01, 2026 which is in 70 days.
How were Wai Yuen Tong Medicine Holdings Limited’s earnings last quarter?
Wai Yuen Tong Medicine Holdings Limited released its earnings results on Jun 25, 2026. The company reported HK$0.001 earnings per share for the quarter.
Is Wai Yuen Tong Medicine Holdings Limited overvalued?
According to Wall Street analysts Wai Yuen Tong Medicine Holdings Limited’s price is currently Overvalued.
Does Wai Yuen Tong Medicine Holdings Limited pay dividends?
Wai Yuen Tong Medicine Holdings Limited pays a Notavailable dividend of HK$0.177 which represents an annual dividend yield of 84.69%. See more information on Wai Yuen Tong Medicine Holdings Limited dividends here
What is Wai Yuen Tong Medicine Holdings Limited’s EPS estimate?
Wai Yuen Tong Medicine Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wai Yuen Tong Medicine Holdings Limited have?
Wai Yuen Tong Medicine Holdings Limited has 1,114,382,900 shares outstanding.
What happened to Wai Yuen Tong Medicine Holdings Limited’s price movement after its last earnings report?
Wai Yuen Tong Medicine Holdings Limited reported an EPS of HK$0.001 in its last earnings report. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Wai Yuen Tong Medicine Holdings Limited?
Currently, no hedge funds are holding shares in HK:0897
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wai Yuen Tong Medicine Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited operates as an investment holding company with a multifaceted business portfolio. Its core activities encompass the production, processing, and retail distribution of traditional Chinese medicines, Western pharmaceuticals, and a range of health and personal care products. These offerings reach customers across Hong Kong, mainland China, Macau, and international markets. The company's Chinese medicine and health food lines are marketed under the Wai Yuen Tong brand, while its Western pharmaceutical and personal care items are available under the Madame Pearl's and Pearl's labels. Beyond its product-focused segments, the group also engages in property investment, ownership, and sales, provides financial services, and oversees an agricultural produce exchange. As of March 31, 2022, Wai Yuen Tong maintained 63 retail stores in Hong Kong. Founded in 1897, the company is headquartered in Kowloon Bay, Hong Kong, and operates as a subsidiary of Rich Time Strategy Limited.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―